PlantEXT has entered into a license agreement with The Government of the State of Israel and has funded research at ARO thus acquiring the exclusive global rights to commercialize ARO’s intellectual property (“IP”) and products based on formulations of active cannabis compounds and possibly other pharmaceutical drugs as a basis for development of products for the treatment of lung inflammation such as the inflammation provoked by COVID-19. (pending final government approval)
Receive updates straight into your inbox
PlantEXT is focusing on products that address an unmet patient need for specific inflammation-related conditions
An entire pipeline of unique, patent-pending cannabis based formulas
Proprietary IBD (Inflammatory Bowel Disease) formulation
Effective delivery systems
Targeted to improved outcomes
Scientifically and clinically proven for efficacy
2300 Yonge Street, Suite 1709
Toronto, ON
M4P 1E4
Developing and commercializing the most effective, clinically evidenced medical cannabis formulations that improve the quality of life for patients across the globe.
